- Home
- MGTX vs CYBN Comparison
MGTX vs CYBN Comparison
Compare MGTX & CYBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MGTX | CYBN |
|---|---|---|
| Founded | 2015 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Pharmaceuticals and Biotechnology |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.7M | 416.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MGTX | CYBN |
|---|---|---|
| Price | $7.96 | $8.33 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $23.83 | ★ $74.50 |
| AVG Volume (30 Days) | 518.4K | ★ 797.2K |
| Earning Date | 11-13-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,417,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $619.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 96.83 | N/A |
| 52 Week Low | $4.55 | $4.81 |
| 52 Week High | $9.73 | $10.73 |
Technical Indicators
Market Signals| Indicator | MGTX | CYBN |
|---|---|---|
| Relative Strength Index (RSI) | 45.34 | 78.09 |
| Support Level | $7.77 | $6.53 |
| Resistance Level | $8.40 | $7.21 |
| Average True Range (ATR) | 0.55 | 0.47 |
| MACD | -0.05 | 0.22 |
| Stochastic Oscillator | 10.69 | 99.07 |
Price Performance
Historical ComparisonAbout MGTX MeiraGTx Holdings plc
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
About CYBN Cybin Inc.
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of its proprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.